Abstract: The invention provides methods and means for distinguishing FECV and FIPV, and methods and means for determining whether FIPV is present in a sample. Further provided are primers and probes for detecting FIPV specific nucleic acid sequences encoding a spike protein, antibodies for detecting a FIPV, and an immunogenic composition and use thereof for eliciting an immune response against a feline coronavirus, preferably a FIPV.
Type:
Application
Filed:
January 18, 2011
Publication date:
March 21, 2013
Applicant:
Universiteit Utrecht Holding B.V.
Inventors:
Petrus Josephus Marie Rottier, Hui-Wen Chang, Herman F. Egberink
Abstract: Coronaviruses can be a significant factor in bovine shipping fever. A new human rectal tumor cell line, HRT-18G, is suitable as a host cell line for the propagation of these bovine respiratory coronavirus-shipping fever viruses, and also is well suited for the propagation of other bovine coronaviruses.
Type:
Grant
Filed:
November 26, 1996
Date of Patent:
October 14, 1997
Assignee:
Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
Abstract: The invention provides antisense antiviral compounds and methods of their use in inhibition of growth of viruses of the picornavirus, calicivirus, togavirus, coronavirus, and flavivirus families, as in treatment of a viral infection. The antisense antiviral compounds are substantially uncharged oligomers having a targeting base sequence that is substantially complementary to a viral target sequence which spans the AUG start site of the first open reading frame of the viral genome.
Type:
Application
Filed:
April 24, 2003
Publication date:
December 4, 2003
Inventors:
David A. Stein, Douglas E. Skilling, Patrick L. Iversen, Alvin W. Smith
Abstract: The disclosure relates to polypeptides, vaccines and pharmaceutical compositions that find use in the prevention or treatment of Coronaviridae or SARS-CoV-2 infection. The disclosure also relates to methods of treating or preventing Coronaviridae or SARS-CoV-2 infection in an individual. The polypeptides and vaccines comprise T cell and/or B cell epitopes that are immunogenic in a high percentage of individuals in the human population.
Type:
Grant
Filed:
April 7, 2020
Date of Patent:
April 13, 2021
Assignee:
PepTC Vaccines Limited
Inventors:
Zsolt Csiszovszki, Orsolya Lörincz, Levente Molnár, Péter Páles, Katalin Pántya, Eszter Somogyi, József Tóth, Enikö R. Töke
Abstract: Provided is a method for determining whether a feline is infected with pathogenic Feline Infectious Peritonitis Virus (FIPV) or Feline Enteric Infection Virus (FECV). The method involves determining the presence or absence of intact or mutated S1/S2 and S2? cleavage sites in the spike protein of serotype 1 feline coronaviruses (FCoV1). The presence of both intact cleavage sites is indicative of FECV. The presence of a mutation in one or both cleavage sites is indicative of FIPV. The absence of both sites is indicative of an absence of FCoV1 infection. Compositions for use in determining infection and kits are also provided.
Abstract: The present invention provides binding molecules that specifically bind to SARS-CoV, nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules and methods of identifying or producing the binding molecules. The binding molecules are capable of specifically binding to SARS-CoV and can be used in the diagnosis, prophylaxis and/or treatment of a condition resulting from SARS-CoV.
Type:
Grant
Filed:
January 20, 2006
Date of Patent:
April 13, 2010
Assignee:
Crucell Holland B.V.
Inventors:
Jan H. Ter Meulen, Cornelis A. De Kruif, Edward N. Van Den Brink, Jaap Goudsmit
Abstract: Coronaviruses can be a significant factor in bovine shipping fever. A new human rectal tumor cell line, HRT-18G, is suitable as a host cell line for the propagation of these bovine respiratory coronavirus-shipping fever viruses, and also is well suited for the propagation of other bovine coronaviruses.
Type:
Grant
Filed:
June 15, 1994
Date of Patent:
December 3, 1996
Assignee:
Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
Abstract: Described are binding molecules that specifically bind to SARS-CoV, nucleic acid molecules encoding the binding molecules, compositions comprising the binding molecules, and methods of identifying or producing the binding molecules. The binding molecules are capable of specifically binding to SARS-CoV, and can be used in the diagnosis, prophylaxis, and/or treatment of a condition resulting from SAR.
Type:
Application
Filed:
November 16, 2009
Publication date:
July 8, 2010
Applicant:
Crucell Holland B.V.
Inventors:
Jan H. Ter Meulen, Cornelis A. De Kruif, Edward N. Van Den Brink, Jaap Goudsmit
Abstract: Provided is a method for determining whether a feline is infected with pathogenic Feline Infectious Peritonitis Virus (FIPV) or Feline Enteric Infection Virus (FECV). The method involves determining the presence or absence of intact or mutated S1/S2 and S2? cleavage sites in the spike protein of serotype 1 feline coronaviruses (FCoV1). The presence of both intact cleavage sites is indicative of FECV. The presence of a mutation in one or both cleavage sites is indicative of FIPV. The absence of both sites is indicative of an absence of FCoV1 infection. Compositions for use in determining infection and kits are also provided.
Abstract: The subject invention relates to a multiple-allelic RT-real-time polymerase chain reaction (PCR) assay for coronaviruses including the SARS virus. Multiple target sequences within the SARS-CoV, S, E, M and N genes are identified. The use of the four different targets enhances the likelihood that the fundamental genetic drift of the virus will not lead to a false negative result. Multiplex assays format for the assay are envisioned. Thus, the present invention allows for early diagnosis of a SARS infection. The assay would be useful in the context of monitoring treatment regimens, screening potential anti SARS agents, and similar applications requiring qualitative and quantitative determinations.
Abstract: The present invention provides monoclonal antibodies that bind to the Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) spike protein, and methods of use. In various embodiments of the invention, the antibodies are fully human antibodies that bind to MERS-CoV spike protein. In some embodiments, the antibodies of the invention are useful for inhibiting or neutralizing MERS-CoV activity, thus providing a means of treating or preventing MERS infection in humans. In some embodiments, the invention provides for a combination of one or more antibodies that bind to the MERS-CoV spike protein for use in treating MERS infection. In certain embodiments, the one or more antibodies bind to distinct non-competing epitopes comprised in the receptor binding domain of the MERS-CoV spike protein.
Type:
Grant
Filed:
June 26, 2017
Date of Patent:
September 10, 2019
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Christos Kyratsous, Neil Stahl, Sumathi Sivapalasingam
Abstract: The present invention relates to methods of preparing a DNA comprising steps, wherein (a) a DNA comprising a full length copy of the genomic RNA (gRNA) or an RNA virus; or (b) a DNA comprising one or several fragments of a gRNA of an RNA virus, which fragments code for an RNA dependent RNA polymerase and at least one structural or non-structural protein; or (c) a DNA having a homology of at least 60% to the sequences of (a) or (b); is cloned into a bacterial artificial chromosome (BAC). Additionally, DNAs are provided, which comprise sequences derived from the genomic RNA (gRNA) of a coronavirus which sequences have a homology of at least 60% to the natural sequence of the virus and code for an RNA dependent RNA polymerase and at least one structural or no-structural protein, wherein a fragment of said DNA is capable of being transcribed into RNA which RNA can be assembled to a virion.
Abstract: The present invention relates to a recombinant severe acute respiratory syndrome coronavirus (SARS-CoV) non-structural protein (nsp) 12 with an RNA polymerase activity, its expression vector, its preparation method, and its use. According to the present invention, a soluble recombinant SARS-CoV nsp12 with an RdRp activity of initiating SARS-CoV genome synthesis can be over-expressed in the transformed host cells, and conveniently purified with high purity. An in vitro replication system important for studying SARS-CoV replication can be established with the purified recombinant SARS-CoV nsp12. SARS-CoV nsp12 produced by the present invention can also be used as a target for the development of anti-viral agents against SARS-CoV. In addition, materials inhibiting RNA-dependent RNA polymerase (RdRp) activity of nsp12 can be screened efficiently according to the present invention as the optimal conditions for the RdRp assay with SARS-CoV nsp12 were found.
Type:
Grant
Filed:
June 13, 2008
Date of Patent:
June 25, 2013
Assignee:
Industry-Academic Cooperation Foundation, Yonsei University Kookmin University Industry Academy Cooperation Foundation